Two Sigma Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-120,605
| Closed | -$704K | – | 3328 |
|
|
2022
Q4 | $704K | Sell |
120,605
-247,347
| -67% | -$1.3M | ﹤0.01% | 1872 |
|
|
2022
Q3 | $2.46M | Buy |
367,952
+129,476
| +54% | +$785K | 0.01% | 1065 |
|
|
2022
Q2 | $1M | Buy |
238,476
+226,476
| +1,887% | +$896K | ﹤0.01% | 1542 |
|
|
2022
Q1 | $40K | Sell |
12,000
-78,900
| -87% | -$250K | ﹤0.01% | 2504 |
|
|
2021
Q4 | $286K | Buy |
90,900
+54,476
| +150% | +$181K | ﹤0.01% | 3678 |
|
|
2021
Q3 | $119K | Sell |
36,424
-8,576
| -19% | -$30K | ﹤0.01% | 4062 |
|
|
2021
Q2 | $190K | Sell |
45,000
-117,597
| -72% | -$498K | ﹤0.01% | 3797 |
|
|
2021
Q1 | $811K | Buy |
162,597
+133,844
| +465% | +$1.08M | ﹤0.01% | 2507 |
|
|
2020
Q4 | $363K | Sell |
28,753
-3,439
| -11% | -$39.2K | ﹤0.01% | 2729 |
|
|
2020
Q3 | $316K | Sell |
32,192
-11,939
| -27% | -$118K | ﹤0.01% | 2556 |
|
|
2020
Q2 | $439K | Sell |
44,131
-10,228
| -19% | -$98.1K | ﹤0.01% | 2087 |
|
|
2020
Q1 | $481K | Sell |
54,359
-21,295
| -28% | -$210K | ﹤0.01% | 1956 |
|
|
2019
Q4 | $698K | Sell |
75,654
-46,905
| -38% | -$332K | ﹤0.01% | 2524 |
|
|
2019
Q3 | $721K | Buy |
122,559
+17,803
| +17% | +$189K | ﹤0.01% | 2257 |
|
|
2019
Q2 | $1.26M | Buy |
104,756
+71,006
| +210% | +$764K | ﹤0.01% | 1752 |
|
|
2019
Q1 | $407K | Sell |
33,750
-7,789
| -19% | -$115K | ﹤0.01% | 2406 |
|
|
2018
Q4 | $521K | Sell |
41,539
-29,367
| -41% | -$405K | ﹤0.01% | 2073 |
|
|
2018
Q3 | $1.05M | Buy |
70,906
+28,356
| +67% | +$446K | ﹤0.01% | 1938 |
|
|
2018
Q2 | $716K | Buy |
+42,550
| New | +$826K | ﹤0.01% | 2398 |
|
|
2018
Q1 | – | Sell |
-151,875
| Closed | -$3.93M | – | 3630 |
|
|
2017
Q4 | $3.93M | Buy |
+151,875
| New | +$3.06M | 0.01% | 1017 |
|
|
2017
Q2 | – | Sell |
-48,900
| Closed | -$834K | – | 3374 |
|
|
2017
Q1 | $834K | Buy |
+48,900
| New | +$586K | ﹤0.01% | 2033 |
|
|
2016
Q2 | – | Sell |
-31,340
| Closed | -$428K | – | 3331 |
|
|
2016
Q1 | $428K | Buy |
+31,340
| New | +$451K | ﹤0.01% | 2160 |
|
|
2015
Q2 | – | Sell |
-70,096
| Closed | -$1.06M | – | 3178 |
|
|
2015
Q1 | $1.06M | Buy |
70,096
+24,933
| +55% | +$348K | ﹤0.01% | 1540 |
|
|
2014
Q4 | $602K | Buy |
+45,163
| New | +$583K | ﹤0.01% | 1634 |
|
Two Sigma Investments's CNCE Position: Q1 2023 in Review
Two Sigma Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 120,605 shares — an estimated $704K sold.
Two Sigma Investments first reported a position in CNCE in Q4 2014 and held it in 24 quarters. The position peaked at $3.93M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Two Sigma Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Two Sigma Investments sold 120,605 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $704K.
- Two Sigma Investments first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
- Two Sigma Investments's Concert Pharmaceuticals, Inc. position peaked at $3.93M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.